

Precirix appoints leading radiopharmaceutical and oncology experts to newly formed Scientific Advisory Board

Brussels, Belgium, 4 October 2023 – Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals for oncology patients, announces the formation of its Scientific Advisory Board (SAB) to guide next steps of development for its differentiated radiopharmaceutical pipeline. Composed of world-renowned leaders in the fields of radiopharmaceuticals and oncology, the SAB will be led by newly appointed Chair, Dr. Jason Lewis.

“Formation of the SAB coincides with the progress of our two lead programs – HER2-directed, iodinated single-domain antibody based CAM-H2 advancing through Phase 1 dose escalation, and our FAP-program approaching the clinic.”, said CEO Ruth Devenyns. “We are honored to have such remarkable and knowledgeable scientific leaders join us in our mission to develop novel radiopharmaceuticals for cancer patients. These experts have made significant contributions and performed pioneering research in the field. We look forward to leveraging their diverse experience as we further develop and advance our pipeline.”

Members of Precirix' SAB include:

Jason S. Lewis, PhD

Emily Tow Chair in Oncology at Memorial Sloan Kettering Cancer Center (MSK)

Vice Chair for Research and Chief Attending of the Radiochemistry & Imaging Sciences Service in MSK's Department of Radiology

Laboratory Head in the Sloan Kettering Institute's Molecular Pharmacology Program

Dr. Lewis is an expert in the field of molecular imaging and the development of radiopharmaceuticals for the diagnosis and treatment of cancer. He has published over 350 papers, books, book chapters, and reviews in the field of cancer imaging. He earned a B.Sc. in Chemistry and a M.Sc. in Chemistry from the University of Essex. He obtained a Ph.D. in Biochemistry from the University of Kent and was a postdoctoral researcher at the Washington University School of Medicine (WUSM). He subsequently joined the WUSM faculty as an Assistant Professor at the Mallinckrodt Institute of Radiology. In 2008 he joined MSKCC, where he is a Member. He is also a Professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences and at Weill Cornell Medical College.

Razelle Kurzrock, MD, PhD

Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center

Associate Director of Precision Oncology at the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine

Founding Director of the Michels Rare Cancers Research Laboratories

Dr. Razelle Kurzrock, a leader in precision medicine and the development of novel cancer therapies, has been listed as one of the most important voices in precision medicine and is on the Web of Science list of most cited scientists globally. She has over 950 peer reviewed publications and has been principal investigator for over 100 early phase clinical trials, including early trial of 8 FDA-approved drugs. She is the Chair for the Early Therapeutics and Rare Cancers Committee (SWOG NCI), and along with the DART rare cancer study team, received the National Cancer Institute Director's Award of Merit for Outstanding Work. Previously, she was Director of both the Center for Personalized Cancer Therapy and the Experimental Therapeutics Program, and Founder of the Rare Tumor Clinic at Moores Cancer Center at UC San Diego Health. Dr. Kurzrock is recognized for founding, developing and chairing one of the largest Phase I clinical trial departments globally while at the University of Texas MD Anderson Cancer Center. She has held Board positions in the National Comprehensive Cancer Network (NCCN), and currently is on the Board of the SWOG Cancer Research Network and WIN Consortium in cancer personalized medicine. She has an MD from the University of Toronto, and completed a Residency in Internal Medicine at Tulane University Hospital, and a Fellowship in Medical Oncology at MD Anderson.

Jean-Pierre Pouget, PhD

Research Director, Team Leader at the French National Institute for Health and Medical research (INSERM)

Dr. Jean-Pierre Pouget obtained his PhD in Radiobiology from the Curie Institute in Paris and performed a post-doctoral fellowship at the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry. He then joined the French Radiation Protection and Nuclear Safety Agency (IRSN) and subsequently the French National Institute for Health and Medical research (INSERM) where he now is team leader of the Radiobiology and Targeted Radiotherapy group at the Cancer Research Institute of Montpellier. Dr. Pouget's research focuses on the development of new radiopharmaceuticals for cancer imaging and therapy, unravelling the role of targeted (radiative) and non-targeted (bystander and systemic) effects of molecular radiotherapy involving intercellular communications and/or the involvement of the immune system. He has published more than 90 papers and book chapters on topics in radiobiology and radionuclide therapy and several patents.

George Sgouros, PhD

Professor of Radiology and Radiological Science at Johns Hopkins University

Director Radiological Physics Division at the Department of Radiology and Director of Radiopharmaceutical Dosimetry at Johns Hopkins University

Dr. Sgouros received his undergraduate degree in applied physics from Columbia University. He obtained his PhD from Cornell University and performed a fellowship in medical physics at Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center in New York, where he was Associate Professor. Dr. Sgouros is a Member of the Johns Hopkins Kimmel Cancer Center. His research focuses on modeling and dosimetry of

4 October 2023

internally administered radionuclides with a particular emphasis on patient-specific dosimetry, alpha-particle dosimetry, and mathematical modeling of radionuclide therapy. Dr. Sgouros chaired multiple committees, including the SNMMI MIRD Committee, an ICRU Committee on dosimetry for radiopharmaceutical therapy, an NIH grant review panel and most recently, organized RPT-TEC (RPT-Tissue Effects in the Clinic) to help consolidate dose-response data for radiopharmaceutical therapeutics.

Gary Ulaner, MD, PhD

James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy at Hoag Family Cancer Institute, Professor of Radiology and Translational Genomics, University of Southern California

Dr. Ulaner is a recognized expert in the use of targeted imaging to help direct focused cancer therapies; he is dual-board certified in radiology and nuclear medicine. He completed his medical degree and Ph.D. in Cancer Biology at Stanford University School of Medicine, an internship at Johns Hopkins Hospital, and his Radiology and Nuclear Medicine residencies at the University of Southern California. Before joining Hoag, he served as the PET/CT expert on the Breast Cancer and Myeloma Disease Management Teams of the Memorial Sloan Kettering Cancer Center. Today, Dr. Ulaner leads several National Institutes of Health (NIH) clinical trials in molecular imaging and therapeutics. Dr. Ulaner has authored or co-authored more than 150 peer-reviewed manuscripts, has given more than 200 national and international presentations and wrote a textbook on the fundamentals of oncologic PET/CT.

About Precirix

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. Precirix' lead program, HER2-directed radioligand CAM-H2 (¹³¹Iodine), is currently enrolling in Phase 1 dose escalation at sites in North America. A second program, targeting Fibroblast Activation Protein, is transitioning into the clinic. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix' technology allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a therapeutic dose for treatment.

For further information, please contact:

Precirix NV

Stéphanie Put, PhD, Head of Corporate Development

+32 2 479 93 60

info@precirix.com

www.precirix.com